Clinical trials: Hep A
Hepatitis C
Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)
The objective of this study is to identify a safe dose of MK-2248 in participants with Hepatitis C Virus (HCV) that mediates at least a 3 log10 reduction in viral load (VL) from baseline.
- Trial name
- NCT02161510
- Testing
- MK-2248
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Portal Hypertension
Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir
Portal hypertension is a common pathology in chronic liver disease, particularly in liver cirrhosis. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China.
- Trial name
- NCT02945982
- Testing
- Entecavir+Carvedilol, Entecavir+Carvedilol+ Fuzheng Huayu
- Where
- 3 sites in China
- Volunteers
- 184 people
- Sponsor
- ShuGuang Hospital
Healthy
A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321
This is a single centre, three single administrations (Days 1, 29 and 57) at increasing doses of IMP321 (3, 10, 30 and 100 µg) in four cohorts of 12 subjects, single blind, randomized study.
- Trial name
- NCT00354861
- Testing
- hepatitis B antigen (without alum) plus IMP321, hepatitis B antigen alone (without alum), Engerix B
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Immutep S.A.S.
Hepatitis B, Chronic, Hepatitis C, Chronic
Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
The investigators' pilot study indicates that hepatitis C virus (HCV)- and hepatitis B virus (HBV)-coinfected patients with predominantly active hepatitis C and those with predominantly active hepatitis B may need different…
- Trial name
- NCT00154869
- Testing
- Peginterferon Alfa-2a plus Ribavirin
- Where
- Taiwan
- Volunteers
- 320 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis C
Pioglitazone in Hepatitis C
The presence of insulin resistance (IR) appears to be a key factor in the development of steatosis and disease progression in patience with Hepatitis C virus (HCV) genotype-1 infections similar to levels in Non-alcoholic fatty…
- Trial name
- NCT00189163
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Hepatitis C, HIV
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Primary Objective: This study will evaluate the effectiveness of an HCV Care Facilitation intervention in moving HIV/HCV co-infected substance users forward along the HCV care continuum (compared with a Control group).
- Conditions
- Hepatitis C, HIV, AIDS, Substance Use
- Trial name
- CTN 0064 (NCT02641158)
- Testing
- Control Group, Care Facilitation Group
- Where
- 11 sites in United States
- Volunteers
- 422 people
- Sponsor
- Columbia University
Hepatitis B Virus, Allograft
Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting
The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.
- Conditions
- Hepatitis B Virus, Allograft, Hematological Malignancies
- Trial name
- NCT00876148
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Hepatitis B
New Methods to Measure the Immune Response to Hepatitis B Vaccine
Hepatitis B vaccine is a safe and effective vaccine used widely throughout the world. Because of this it is a useful vaccine in which to develop new methods for studying immune responses.
- Trial name
- NCT01821547
- Testing
- Hepatitis B vaccine
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Acute on Chronic Hepatic Failure, Liver Failure
The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure
This is a multicenter, randomized, controlled, open-label phase 1/2 clinical study conducted in China to evaluate the efficacy, safety and tolerability of hiHep cell-based bio-artificial liver support system (HepaCure) plus DPMAS…
- Conditions
- Acute on Chronic Hepatic Failure, Liver Failure, Hepatitis
- Trial name
- NCT05989958
- Testing
- HepaCure, DPMAS and LPE
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Hexaell Biotech Co., Ltd.
Hepatitis C, Depressive Disorder, Major
Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients
The purpose of this study is to determine whether cognitive behavioral therapy (CBT) is effective in the prevention of depression during interferon and ribavirin treatment for hepatitis C infection.
- Conditions
- Hepatitis C, Depressive Disorder, Major, Depressive Disorder, Depression
- Trial name
- NCT00655226
- Testing
- Hepatitis C educational support groups, Cognitive Behavioral Therapy skills based group sessions
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
HCV Infection
Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection
This study is to determine the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV) fixed-dose combination (FDC) with and without ribavirin (RBV), and to evaluate the safety and tolerability of each regimen as assessed by…
- Trial name
- NCT01965535
- Testing
- LDV/SOF, RBV
- Where
- 19 sites in France
- Volunteers
- 155 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis D Infection
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD).
- Trial name
- NCT07200908
- Testing
- Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg
- Where
- 57 sites in Austria, Czechia and 10 more
- Volunteers
- 172 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Hepatitis, Chronic Active
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RBV) compared to PEG-IFN and RBV without CPG 10101 in…
- Trial name
- NCT00277238
- Testing
- CPG10101, Control
- Where
- 14 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pfizer
HIV Infection, Hepatitis C
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis
- Trial name
- NCT00141284
- Testing
- nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily
- Where
- 5 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Pfizer
HIV, Hepatitis C
Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV
The ANRS CO13 HEPAVIH cohort is a prospective and multicentric cohort created in 2005 with the originality to cover two therapeutic domains of key importance, AIDS and hepatitis C.
- Trial name
- CO13Hepavih (NCT03324633)
- Volunteers
- 1,850 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Inflammatory Bowel Disease (IBD), Hepatitis B Virus
Impact of Hepatitis B Virus on Inflammatory Bowel Disease
The goal of this observational retrospective study is to assess the impact of hepatitis B virus (HBV) infection on the clinical course and outcomes of inflammatory bowel disease (IBD) in Egyptian patients.
- Trial name
- NCT06881238
- Testing
- History of IBD course and outcome in HBV patients
- Where
- Egypt
- Volunteers
- 162 people
- Sponsor
- Tanta University
Hepatitis B, Chronic
A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection
This is a double-blinded, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics, and antiviral activity in both healthy volunteers and volunteers with chronic hepatitis B virus infection.
- Trial name
- NCT04248426
- Testing
- ATI-2173
- Where
- 3 sites in Canada, Moldova and 1 more
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Antios Therapeutics, Inc
Chronic Hepatitis C
Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)
This is a three-part (Part A, Part B, and Part C), open-label, multicenter study of boceprevir in pediatric participants with chronic hepatitis C (CHC) genotype 1 (GT1).
- Trial name
- NCT01590225
- Testing
- Boceprevir, Peginterferon alpha-2b, Ribavirin
- Sponsor
- Merck Sharp & Dohme LLC
Porphyria Cutanea Tarda, Hepatitis C
Harvoni Treatment Porphyria Cutanea Tarda
In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested.
- Trial name
- NCT03118674
- Testing
- Harvoni
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Hepatitis C Infection
Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)
The purpose of this 3-part study is to evaluate the potential impact of simeprevir and food on pharmacokinetics (PK) of IDX719 in healthy participants. Part 1 will evaluate potential PK interactions between IDX719 and simeprevir.
- Trial name
- NCT01813513
- Testing
- IDX719, Simeprevir
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.